Journal article
Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts
Abstract
Targeting the renin-angiotensin system and optimizing tacrolimus exposure are both postulated to improve outcomes in renal transplant recipients (RTRs) by preventing interstitial fibrosis/tubular atrophy (IF/TA). In this multicenter, prospective, open-label controlled trial, adult de novo RTRs were randomized in a 2 × 2 design to low- vs standard-dose (LOW vs STD) prolonged-release tacrolimus and to angiotensin-converting enzyme …
Authors
Cockfield SM; Wilson S; Campbell PM; Cantarovich M; Gangji A; Houde I; Jevnikar AM; Keough‐Ryan TM; Monroy‐Cuadros F; Nickerson PW
Journal
American Journal of Transplantation, Vol. 19, No. 6, pp. 1730–1744
Publisher
Elsevier
Publication Date
June 2019
DOI
10.1111/ajt.15225
ISSN
1600-6135
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAllograftsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtrophyDelayed-Action PreparationsDrug Therapy, CombinationFemaleFibrosisGraft RejectionHumansImmunosuppressive AgentsKidneyKidney TransplantationMaleMiddle AgedPolyomavirus InfectionsPrognosisProspective StudiesRenin-Angiotensin SystemTacrolimusVirus Activation